Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   24/12/2025
176,33 USD (+0,86%)
(+0,86%)   24/12/2025

22 december 2025 · The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS · Persbericht

5 december 2025 · Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting · Persbericht

4 december 2025 · Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 · Persbericht

2 december 2025 · New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF · Persbericht

25 november 2025 · Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status · Persbericht

24 november 2025 · Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions · Persbericht

17 november 2025 · Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments · Persbericht

17 november 2025 · High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy · Persbericht

14 november 2025 · Biogen Completes Acquisition of Alcyone Therapeutics · Persbericht

3 november 2025 · Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 · Persbericht

24 oktober 2025 · Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio · Persbericht

22 oktober 2025 · Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 · Persbericht

14 oktober 2025 · LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” · Persbericht

14 oktober 2025 · LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" · Persbericht

9 oktober 2025 · Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome · Persbericht

6 oktober 2025 · Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease · Persbericht

6 oktober 2025 · Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease · Persbericht

29 september 2025 · “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China · Persbericht

24 september 2025 · LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia · Persbericht

23 september 2025 · Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen · Persbericht

Mijn selecties